Simulating the Release Mechanism in Drug-Eluting Stents

Slides:

Advertisements

Similar presentations

Nelson Research, Inc – N. 88 th St. Seattle, WA USA aol.com Heterogeneous Reacting Fluid Flow in Catalytically Active.

Advertisements

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.

Example: Simulation of Electrochemical Impedance Spectroscopy

Drug Coated Balloons From Bench to Bedside Service de Radiodiagnostic et Radiologie Interventionnelle Université de Lausanne Salah D. Qanadli, MD, PhD,

Dynamic model of a drop shot from an inkjet printer.

Prof. Dr. Nenad Filipovic 1,2 1) Faculty of Mechanical Engineering, University of Kragujevac, Kragujevac, Serbia 2) Harvard School of Public Health, Boston,

Results and Discussion Loren Connell Eric Skibbe.

Aim of work The main objective of this investigation was to optimize the formulation of chitosan beads with Ketorolac tromethamine to minimize the gastrointestinal.

Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.

1 Advisory Committee for Pharmaceutical Science May 3, 2005 Factors Impacting Drug Dissolution and Absorption : Current State of Science Lawrence X. Yu,

Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer

© Copyright ASD GmbH 2006 ASD ASD Advanced Simulation & Design GmbH Virtual product development in medical technology and engineering

Boston Scientific Drug eluting stent program A Scientific Approach Identify therapeutic agent Identify appropriate polymer carrier Evaluate a broad range.

Weekly Report Sept. 19 th -Sept. 23 rd Federico Viscarra Sept. 23 rd, 2011 Davila research group.

The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

In Vivo Evaluation of 5-Fluorouracil-Containing Self-Expandable Nitinol Stent in Rabbits: Efficiency in Long-Term Local Drug Delivery Sheng-Rong Guo,

Josiah N. Wilcox, Ph.D. Chief Scientific Officer

From: Coating Techniques and Release Kinetics of Drug-Eluting Stents

Abbott Vascular Bifurcation Program

CHAPTER 7 ABSORPTION KINETICS.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Date of download: 10/27/2017 Copyright © ASME. All rights reserved.

One DES Eluting Two Drugs: Is it Feasible?

Enzymes and drugs P450 enzymes breakdown/metabolize active drug

Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.

Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Drug-Eluting Bioabsorbable.

Medtronic Non-Polymeric DES Development: Update on the Drug Filled Stent Josiah N. Wilcox, Ph.D. Vice President and Resident Scholar Science and Technology.

Are we using fewer Covered Stents for SFA Occlusive Disease?

New Frontiers in Cardiology

Darts Sciences Darts Target Identification.

Present By:- Company Name: Global Market Forecastes Tel: / Web:

Passive Transport This is going to show how cells transport substances in and out. 1.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

منهج البحث العلمي ( Scientific Research Method )

Advancements in Intracoronary Stents

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Fig 6.1 Drug released by diffusion

Бази от данни и СУБД Основни понятия инж. Ангел Ст. Ангелов.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Venugopal Vijayan, Munuswamy Purushothaman, James Anbu Raj

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent- mediated delivery of everolimus Hugh Q. Zhao, PhD, Alexander.

The Sweet Side of Simulation Behind the Scenes at Nestlé

Optimizing Ultrasound Piezo-Disk Transducers

Innovative Motor Designs for Electric Cars Come to Life

Multiphysics Modeling in the Biopharma Industry

Naval Research Laboratory, Washington DC, USA

Invisible Connections Will Unveil Our 5G Future

Boston Scientific, MN, USA Travis Schauer and Ismail Guler

Defending Automotive Components Against Corrosive Destruction

Revving up Electrohydraulic Power Steering with Virtual Prototyping

WiTricity Leverages Magnetic Resonance for Flexible Wireless Charging

Highly Accurate Li-ion Battery Simulation

Simulation-LED Strategy for Corrosion Prevention

Researching a New Fuel for the HFIR: Advancements at ORNL Require Multiphysics Simulation to Support Safety and Reliability Redesign High Flux Isotope.

3D Parametric Full Eye Model Gives 20+ Years of Better Vision

Reliable Structures and Wearable Systems Call for Multiphysics Simulation The goal is to understand multiphysics interactions at every stage of the development.

American College of Cardiology Presented by Dr. Adnan Kastrati

Maria Alejandra Restrepo-Cordoba et al. JCIN 2016;9:e137-e139

On the Cutting Edge of Hearing Aid Research

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

Medtronic Advances Ablation Technology with Multiphysics Simulation

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Flow patterns of 2 vertebral artery fusiform cases with different stent-placement strategies. Flow patterns of 2 vertebral artery fusiform cases with different.

Drug-eluting coronary stent market overview

Presentation transcript:

Simulating the Release Mechanism in Drug-Eluting Stents Developed pore-shell model of the coating on drug-eluting stents to investigate the release mechanism and improve design Simulation results confirm a fast release mechanism from pores and slow diffusion from shell; excellent agreement with in vitro experiments COMSOL News 2014: Travis Schauer and Ismail Guler, Boston Scientific, MN, USA Stent insertion and expansion in an artery. Simulation results in COMSOL Multiphysics®: predicted drug concentration for the in vitro case at t = 2 hrs.